Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
Portfolio Pulse from Lisa Levin
Several Wall Street analysts have updated their price targets and ratings for various companies. Can-Fite BioPharma, Arvinas, FMC Corporation, NerdWallet, Shockwave Medical, Bloom Energy Corporation, and Floor & Decor Holdings had their price targets cut by different analysts. Meanwhile, Medpace Holdings, Golden Ocean Group Limited, and Matson saw their price targets increased.
October 24, 2023 | 1:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays slashed the price target for Arvinas from $39 to $26.
The reduction in price target by Barclays could lead to a negative sentiment among investors, potentially causing a short-term decrease in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Can-Fite BioPharma's price target was cut from $34 to $18 by HC Wainwright & Co.
The significant cut in price target by a major analyst could negatively impact investor sentiment and potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Fermium Research lowered FMC Corporation's price target from $85 to $62.
The decrease in price target by Fermium Research could negatively impact investor sentiment, potentially leading to a short-term decrease in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Jefferies increased the price target for Golden Ocean Group Limited from $8 to $11.
The increase in price target by Jefferies could lead to a positive sentiment among investors, potentially causing a short-term increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Wolfe Research increased Matson's price target from $113 to $116.
The increase in price target by Wolfe Research could lead to a positive sentiment among investors, potentially causing a short-term increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Baird raised the price target for Medpace Holdings from $270 to $289.
The increase in price target by Baird could lead to a positive sentiment among investors, potentially causing a short-term increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100